Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study

Fig. 3

Flowchart of inclusion of eligible patients in this self-controlled case series study. Patients who had received SGLT2i and/or metformin after the diagnosis of type 2 diabetes were included in the current analysis. Those with stage 4–5 chronic kidney disease, dialysis, renal transplant, or erythrocytosis before the start of observation (1st January 2015) were excluded. In total, 20,861 patients with type 2 diabetes and metformin and/or SGLT2i prescription records on or after 1st January 2015 were identified

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840